Status:
RECRUITING
Exercise Therapy for Isotretinoin Users
Lead Sponsor:
Uşak University
Conditions:
Isotretinoin
Isotretinoin Adverse Reaction
Eligibility:
All Genders
18-35 years
Phase:
NA
Brief Summary
Isotretinoin (13-cis retinoic acid) is a retinoic acid that is a derivative of vitamin A. Isotretinoin has been used effectively alone in acne treatment for 35 years. However, it has many side effects...
Detailed Description
Isotretinoin (13-cis retinoic acid) is a vitamin A derivative of retinoic acid. It was approved by the FDA in 1982 for the treatment of severe, refractory nodulocystic acne. Isotretinoin has been used...
Eligibility Criteria
Inclusion
- The participant is between the ages of 18-35,
- Not having a regular exercise habit,
- Starting Isotretinoin treatment for the first time.
Exclusion
- Presence of any diagnosed rheumatologic disease,
- The presence of any diagnosed neurological disease,
- Having any diagnosed psychiatric illness,
- Having a physical disability that prevents them from exercising for any reason.
Key Trial Info
Start Date :
September 30 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 26 2026
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT07196787
Start Date
September 30 2025
End Date
March 26 2026
Last Update
December 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Usak University
Uşak, Turkey (Türkiye), 64200